Quarterly Report (10-q)

Date : 06/13/2019 @ 9:17PM
Source : Edgar (US Regulatory)
Stock : Streamline Health Solutions Inc (STRM)
Quote : 1.11  0.02 (1.83%) @ 11:01PM

Quarterly Report (10-q)

 

 

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 10-Q

 

 

 

(Mark One)

 

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 30, 2019

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from               to

Commission File Number: 000‑28132


 

STREAMLINE HEALTH SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

    

31‑1455414

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer
Identification No.)

 

1175 Peachtree Street, NE, 10th Floor

Atlanta, GA 30361

(Address of principal executive offices) (Zip Code)

(888) 997‑8732

(Registrant’s telephone number, including area code)

 


Securities registered pursuant to Section 12(b) of the Act:

 

 

 

 

 

 

 

 

 

 

 

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, $0.01 par value

STRM

Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.

 

 

 

 

Large accelerated filer 

Accelerated filer

Non-accelerated filer ☒

Smaller reporting company ☒

 

 

 

 

Emerging growth company 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Exchange Act).   Yes          No ☒

The number of shares outstanding of the Registrant’s Common Stock, $.01 par value, as of May 31, 2019: 21,069,384

 

 

 

 

 

TABLE OF CONTENTS

 

 

Page

Part I.  

FINANCIAL INFORMATION

2

Item 1.  

Financial Statements

2

 

Condensed Consolidated Balance Sheets at April 30, 2019 and January 31, 2019

2

 

Condensed Consolidated Statements of Operations for the three months ended April 30, 2019 and 2018

4

 

Condensed Consolidated Statements of Stockholders’ Equity for the three months ended April 30, 2019 and 2018

5

 

Condensed Consolidated Statements of Cash Flows for the three months ended April 30, 2019 and 2018

6

 

Notes to Condensed Consolidated Financial Statements

7

Item 2.  

Management’s Discussion and Analysis of Financial Condition and Results of Operations

17

Item 3.  

Quantitative and Qualitative Disclosures About Market Risk

26

Item 4.  

Controls and Procedures

26

Part II.  

OTHER INFORMATION

27

Item 1.  

Legal Proceedings

27

Item 1A.  

Risk Factors

27

Item 6.  

Exhibits

38

 

Signatures

40

 

 

 

PART I. FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS

STREAMLINE HEALTH SOLUTIONS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

(rounded to the nearest thousand dollars,   except share and per share information)

(Unaudited)

 

 

 

 

 

 

 

 

 

As of

 

    

April 30, 2019

    

January 31, 2019

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

2,009,000

 

$

2,376,000

Accounts receivable, net of allowance for doubtful accounts of $43,000 and $345,000, respectively

 

 

2,892,000

 

 

2,933,000

Contract receivables

 

 

1,309,000

 

 

1,263,000

Prepaid and other current assets

 

 

1,425,000

 

 

1,346,000

Total current assets

 

 

7,635,000

 

 

7,918,000

Non-current assets:

 

 

  

 

 

  

Property and equipment, net of accumulated amortization of $1,552,000 and $1,516,000, respectively

 

 

240,000

 

 

237,000

Contract receivables, less current portion

 

 

330,000

 

 

407,000

Capitalized software development costs, net of accumulated amortization of $19,895,000 and $19,689,000, respectively

 

 

6,462,000

 

 

5,698,000

Intangible assets, net of accumulated amortization of $4,000,000 and $3,858,000, respectively

 

 

1,527,000

 

 

1,669,000

Goodwill

 

 

15,537,000

 

 

15,537,000

Other

 

 

252,000

 

 

274,000

Total non-current assets

 

 

24,348,000

 

 

23,822,000

 

 

$

31,983,000

 

$

31,740,000

 

See accompanying notes to condensed consolidated financial statements.

2

STREAMLINE HEALTH SOLUTIONS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

(rounded to the nearest thousand dollars,   except share and per share information)

( Unaudited )

 

 

 

 

 

 

 

 

 

As of

 

    

April 30, 2019

    

January 31, 2019

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

Current liabilities:

 

 

  

 

 

  

Accounts payable

 

$

1,241,000

 

$

1,280,000

Accrued expenses

 

 

990,000

 

 

1,814,000

Current portion of term loan

 

 

597,000

 

 

597,000

Deferred revenues

 

 

9,164,000

 

 

8,338,000

Other

 

 

94,000

 

 

94,000

Total current liabilities

 

 

12,086,000

 

 

12,123,000

Non-current liabilities:

 

 

  

 

 

  

Term loan, net of current portion and deferred financing cost of $69,000 and $82,000, respectively

 

 

3,215,000

 

 

3,351,000

Royalty liability

 

 

920,000

 

 

905,000

Deferred revenues, less current portion

 

 

258,000

 

 

432,000

Other

 

 

34,000

 

 

41,000

Total non-current liabilities

 

 

4,427,000

 

 

4,729,000

Total liabilities

 

 

16,513,000

 

 

16,852,000

Series A 0% Convertible Redeemable Preferred Stock, $.01 par value per share, $8,686,000 redemption value, 4,000,000 shares authorized, 2,895,464 shares issued and outstanding

 

 

8,686,000

 

 

8,686,000

Stockholders’ equity:

 

 

  

 

 

  

Common stock, $.01 par value per share, 45,000,000 shares authorized; 20,902,341 and 20,767,708 shares issued and outstanding, respectively

 

 

209,000

 

 

208,000

Additional paid in capital

 

 

82,812,000

 

 

82,544,000

Accumulated deficit

 

 

(76,237,000)

 

 

(76,550,000)

Total stockholders’ equity

 

 

6,784,000

 

 

6,202,000

 

 

$

31,983,000

 

$

31,740,000

 

See accompanying notes to condensed consolidated financial statements.

3

STREAMLINE HEALTH SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 

(rounded to the nearest thousand dollars, except share and per share information)

 

(Unaudited)

 

 

 

 

 

 

 

 

 

Three Months Ended April 30, 

 

    

2019

    

2018

Revenues:

 

 

 

 

 

 

System sales

 

$

231,000

 

$

1,132,000

Professional services

 

 

581,000

 

 

238,000

Audit services

 

 

395,000

 

 

360,000

Maintenance and support

 

 

2,951,000

 

 

3,309,000

Software as a service

 

 

1,199,000

 

 

1,224,000

Total revenues

 

 

5,357,000

 

 

6,263,000

Operating expenses:

 

 

  

 

 

  

Cost of system sales

 

 

113,000

 

 

250,000

Cost of professional services

 

 

542,000

 

 

706,000

Cost of audit services

 

 

303,000

 

 

394,000

Cost of maintenance and support

 

 

409,000

 

 

648,000

Cost of software as a service

 

 

280,000

 

 

316,000

Selling, general and administrative expense

 

 

2,484,000

 

 

3,250,000

Research and development

 

 

792,000

 

 

1,062,000

Total operating expenses

 

 

4,923,000

 

 

6,626,000

Operating income (loss)

 

 

434,000

 

 

(363,000)

Other expense:

 

 

  

 

 

  

Interest expense

 

 

(78,000)

 

 

(116,000)

Miscellaneous expense

 

 

(41,000)

 

 

(88,000)

Income (loss) before income taxes

 

 

315,000

 

 

(567,000)

Income tax expense

 

 

(2,000)

 

 

(2,000)

Net income (loss)

 

$

313,000

 

$

(569,000)

Net income (loss) per common share - basic

 

$

0.01

 

$

(0.03)

Weighted average number of common shares - basic

 

 

19,793,361

 

 

19,299,309

Net income (loss) per common share - diluted

 

$

0.01

 

$

(0.03)

Weighted average number of common shares - diluted

 

 

22,825,037

 

 

19,299,309

 

See accompanying notes to condensed consolidated financial statements.

 

 

4

STREAMLINE HEALTH SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

 

(rounded to the nearest thousand dollars,   except share information)

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

 

    

 

    

Additional

    

 

 

    

 

 

 

 

Common

 

Common

 

paid in

 

Accumulated

 

Total

 

 

stock shares

 

stock

 

capital

 

deficit

 

stockholders’ equity

Balance at January 31, 2018

 

20,005,977

 

$

200,000

 

$

81,777,000

 

$

(72,125,000)

 

$

9,852,000

Cumulative effect of ASC 606 implementation

 

 —

 

 

 —

 

 

 —

 

 

1,440,000

 

 

1,440,000

Surrender of stock upon vesting of restricted stock to satisfy tax withholding obligations

 

(26,062)

 

 

 —

 

 

(47,000)

 

 

 —

 

 

(47,000)

Conversion of Series A Preferred Stock

 

54,531

 

 

1,000

 

 

163,000

 

 

 —

 

 

164,000

Share-based compensation expense

 

 —

 

 

 —

 

 

222,000

 

 

 —

 

 

222,000

Net loss

 

 

 

 —

 

 

 —

 

 

(569,000)

 

 

(569,000)

Balance at April 30, 2018

 

20,034,446

 

$

201,000

 

$

82,115,000

 

$

(71,254,000)

 

$

11,062,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at January 31, 2019

 

20,767,708

 

$

208,000

 

$

82,544,000

 

$

(76,550,000)

 

$

6,202,000

Stock issued pursuant to Employee Stock Purchase Plan

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

 —

Restricted stock issued

 

140,000

 

 

1,000

 

 

(1,000)

 

 

 —

 

 

 —

Restricted stock forfeited

 

(5,367)

 

 

 —

 

 

 —

 

 

 —

 

 

 —

Share-based compensation expense

 

 —

 

 

 —

 

 

269,000

 

 

 —

 

 

269,000

Net income

 

 

 

 —

 

 

 —

 

 

313,000

 

 

313,000

Balance at April 30, 2019

 

20,902,341

 

$

209,000

 

$

82,812,000

 

$

(76,237,000)

 

$

6,784,000

 

See accompanying notes to condensed consolidated financial statements

 

5

 

STREAMLINE HEALTH SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

(rounded to the nearest thousand dollars)  

(Unaudited)

 

 

 

 

 

 

 

 

 

Three Months Ended April 30, 

 

    

2019

    

2018

Cash flows from operating activities:

 

 

 

 

 

 

Net income (loss)

 

$

313,000

 

$

(569,000)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

 

 

  

 

 

  

Depreciation

 

 

35,000

 

 

171,000

Amortization of capitalized software development costs

 

 

206,000

 

 

315,000

Amortization of intangible assets

 

 

143,000

 

 

235,000

Amortization of other deferred costs

 

 

66,000

 

 

120,000

Valuation adjustments

 

 

15,000

 

 

51,000

Gain on disposal of fixed assets

 

 

 —

 

 

(1,000)

Share-based compensation expense

 

 

269,000

 

 

222,000

Provision for accounts receivable

 

 

(277,000)

 

 

(8,000)

Changes in assets and liabilities:

 

 

  

 

 

  

Accounts and contract receivables

 

 

349,000

 

 

(446,000)

Other assets

 

 

(108,000)

 

 

43,000

Accounts payable

 

 

(39,000)

 

 

923,000

Accrued expenses

 

 

(831,000)

 

 

622,000

Deferred revenues

 

 

652,000

 

 

(1,641,000)

Net cash provided by operating activities

 

 

793,000

 

 

37,000

Cash flows from investing activities:

 

 

  

 

 

  

Purchases of property and equipment

 

 

(38,000)

 

 

(3,000)

Proceeds from sales of property and equipment

 

 

 —

 

 

14,000

Capitalization of software development costs

 

 

(970,000)

 

 

(726,000)

Net cash used in investing activities

 

 

(1,008,000)

 

 

(715,000)

Cash flows from financing activities:

 

 

  

 

 

  

Principal payments on term loan

 

 

(149,000)

 

 

(149,000)

Payments related to settlement of employee shared-based awards

 

 

 —

 

 

(47,000)

Payment of deferred financing costs

 

 

(3,000)

 

 

 —

Net cash used in financing activities

 

 

(152,000)

 

 

(196,000)

Net decrease in cash and cash equivalents

 

 

(367,000)

 

 

(874,000)

Cash and cash equivalents at beginning of period

 

 

2,376,000

 

 

4,620,000

Cash and cash equivalents at end of period

 

$

2,009,000

 

$

3,746,000

 

See accompanying notes to condensed consolidated financial statements.

 

 

6

STREAMLINE HEALTH SOLUTIONS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

April 30, 2019

NOTE 1 — BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared by Streamline Health Solutions, Inc. (“we”, “us”, “our”, “Streamline”, or the “Company”), pursuant to the rules and regulations applicable to quarterly reports on Form 10‑Q of the U.S. Securities and Exchange Commission. Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures made are adequate to make the information not misleading. The condensed consolidated financial statements include the accounts of Streamline Health Solutions, Inc. and its wholly-owned subsidiary, Streamline Health, Inc. In the opinion of our management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the condensed consolidated financial statements have been included. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent annual report on Form 10‑K, Commission File Number 0‑28132. Operating results for the three months ended April 30, 2019 are not necessarily indicative of the results that may be expected for the fiscal year ending January 31, 2020.

 

The Company determined that it has one operating segment and one reporting unit due to the single nature of our products, product development and distribution process, and customer base as a provider of computer software-based solutions and services for healthcare providers.

 

All amounts in the condensed consolidated financial statements, notes and tables have been rounded to the nearest thousand dollars, except share and per share amounts, unless otherwise indicated.

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Our significant accounting policies are presented in “Note 2 – Significant Accounting Policies” in the fiscal year 2018 Annual Report on Form 10‑K. Users of financial information for interim periods are encouraged to refer to the footnotes to the consolidated financial statements contained in the Annual Report on Form 10‑K when reviewing interim financial results.

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Fair Value of Financial Instruments

The Financial Accounting Standards Board’s (“FASB”) authoritative guidance on fair value measurements establishes a framework for measuring fair value. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

7

Level 3: Unobservable inputs that are not corroborated by market data.

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Cash and cash equivalents are classified as Level 1. The carrying amount of our long-term debt approximates fair value since the variable interest rates being paid on the amounts approximate the market interest rate. Long-term debt is classified as Level 2. There were no transfers of assets or liabilities between Levels 1, 2, or 3 during the three months ended April 30, 2019 and 2018.  

 

The table below provides information on our liabilities that are measured at fair value on a recurring basis:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

 

    

Quoted Prices in

    

Significant Other

    

Significant

 

 

Total Fair

 

Active Markets

 

Observable Inputs

 

Unobservable Inputs

 

 

Value

 

(Level 1)

 

 (Level 2)

 

(Level 3)

At April 30, 2019

 

 

  

 

 

  

 

 

  

 

 

  

Royalty liability (1)

 

$

920,000

 

$

 —

 

$

 —

 

$

920,000

 

 

 

 

 

 

 

 

 

 

 

 

 

At January 31, 2019

 

 

  

 

 

  

 

 

  

 

 

  

Royalty liability (1)

 

$

905,000

 

$

 —

 

$

 —

 

$

905,000


(1)

The fair value of the royalty liability was determined based on discounting the portion of the modified royalty commitment payable in cash (refer to Note 7 – Commitments and Contingencies for additional information on our royalty liability). Fair value adjustments are included within miscellaneous expense in the condensed consolidated statements of operations.

Revenue Recognition

We derive revenue from the sale of internally-developed software, either by licensing for local installation or by a software as a service (“SaaS”) delivery model, through our direct sales force or through third-party resellers. Licensed, locally-installed clients on a perpetual model utilize our support and maintenance services for a separate fee, whereas term-based locally installed license fees and SaaS fees include support and maintenance. We also derive revenue from professional services that support the implementation, configuration, training and optimization of the applications, as well as audit services provided to help clients review their internal coding audit processes. Additional revenues are also derived from reselling third-party software and hardware components.

We recognize revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

We commence revenue recognition (Step 5 below) in accordance with that core principle after applying the following steps:

·

Step 1: Identify the contract(s) with a customer

·

Step 2: Identify the performance obligations in the contract

·

Step 3: Determine the transaction price

·

Step 4: Allocate the transaction price to the performance obligations in the contract

·

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation

8

We follow the accounting revenue guidance under ASC 606 to determine whether contracts contain more than one performance obligation. Performance obligations are the unit of accounting for revenue recognition and generally represent the distinct goods or services that are promised to the customer. Revenue is recognized net of any taxes collected from customers and subsequently remitted to governmental authorities.

If we determine that we have not satisfied a performance obligation, we will defer recognition of the revenue until the performance obligation is deemed to be satisfied. Maintenance and support and SaaS agreements are generally non-cancelable or contain significant penalties for early cancellation, although clients typically have the right to terminate their contracts for cause if we fail to perform material obligations. However, if non-standard acceptance periods, non-standard performance criteria, or cancellation or right of refund terms are required, revenue is recognized upon the satisfaction of such criteria.

Significant judgment is required to determine the standalone selling price (“SSP”) for each performance obligation, the amount allocated to each performance obligation and whether it depicts the amount that the Company expects to receive in exchange for the related product and/or service. As the selling prices of the Company’s software licenses are highly variable, the Company estimates SSP of its software licenses using the residual approach when the software license is sold with other services and observable SSPs exist for the other services. The Company estimates the SSP for maintenance, professional services, and audit services based on observable standalone sales.

Contract Combination

The Company may execute more than one contract or agreement with a single customer. The Company evaluates whether the agreements were negotiated as a package with a single objective, whether the amount of consideration to be paid in one agreement depends on the price and/or performance of another agreement, or whether the good or services promised in the agreements represent a single performance obligation. The conclusions reached can impact the allocation of the transaction price to each performance obligation and the timing of revenue recognition related to those arrangements.

Systems Sales

The Company’s software license arrangements provide the customer with the right to use functional intellectual property. Implementation, support, and other services are typically considered distinct performance obligations when sold with a software license unless these services are determined to significantly modify the software. Revenue is recognized at a point in time. Typically, this is upon shipment of components or electronic download of software.

Maintenance and Support Services

Our maintenance and support obligations include multiple discrete performance obligations, with the two largest being unspecified product upgrades or enhancements, and technical support, which can be offered at various points during a contract period. We believe that the multiple discrete performance obligations within our overall maintenance and support obligations can be viewed as a single performance obligation since both the unspecified upgrades and technical support are activities to fulfill the maintenance performance obligation and are rendered concurrently. Maintenance and support agreements entitle clients to technology support, version upgrades, bug fixes and service packs. We recognize maintenance and support revenue ratably over the contract term.

Software-Based Solution Professional Services

The Company provides various professional services to customers with software licenses. These include project management, software implementation and software modification services. Revenues from arrangements to provide professional services are generally distinct from the other promises in the contract and are recognized as the related services are performed. Consideration payable under these arrangements is either fixed fee or on a time-and-materials basis.

9

Software as a Service

SaaS-based contracts include use of the Company’s platform, implementation, support and other services which represent a single promise to provide continuous access to its software solutions. The Company recognizes revenue ratably over the contract term.

We defer the direct costs, which includes salaries and benefits, for professional services related to SaaS contracts. These deferred costs will be amortized over the identical term as the associated revenues. As of April 30, 2019, and January 31, 2019, we had deferred costs of $228,000 and $251,000, respectively, net of accumulated amortization of $448,000 and $399,000, respectively. Amortization expense of these costs was $50,000 and $102,000 for the three months ended April 30, 2019 and 2018, respectively.

Audit Services

Audit services are a separate performance obligation. We recognize revenue over time as the services are performed.

Disaggregation of Revenue

The following table provides information about disaggregated revenue by type and nature of revenue stream:

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended April 30, 2019

 

    

Recurring Revenue

    

Non-recurring Revenue

    

Total

Systems sales

 

$

 —

 

$

231,000

 

$

231,000

Professional services

 

 

 —

 

 

581,000

 

 

581,000

Audit services

 

 

 —

 

 

395,000

 

 

395,000

Maintenance and support

 

 

2,951,000

 

 

 —

 

 

2,951,000

Software as a service

 

 

1,199,000

 

 

 —

 

 

1,199,000

Total revenue:

 

$

4,150,000

 

$

1,207,000

 

$

5,357,000

 

Contract Receivables and Deferred Revenues

The Company receives payments from customers based upon contractual billing schedules. Contract receivables include amounts related to the Company’s contractual right to consideration for completed performance obligations not yet invoiced. Deferred revenues include payments received in advance of performance under the contract. Our contract receivables and deferred revenue are reported on an individual contract basis at the end of each reporting period. Contract receivables are classified as current or noncurrent based on the timing of when we expect to bill the customer. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to recognize revenue. In the three-month period ended April 30, 2019 we recognized $2,909,000 in revenue from deferred revenues outstanding as of January 31, 2019.

Transaction price allocated to the remaining performance obligations

Revenue allocated to remaining performance obligations represents contracted revenue that will be recognized in future periods, which is comprised of deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. Revenue allocated to remaining performance obligations was $25 million as of April 30, 2019, of which the Company expects to recognize approximately 66% over the next 12 months and the remainder thereafter.

Deferred commissions costs (contract acquisition costs)

Contract acquisition costs, which consists of sales commissions paid or payable, is considered incremental and recoverable costs of obtaining a contract with a customer. Sales commissions for initial and renewal contracts are deferred and then amortized on a straight-line basis over a period of benefit, which the Company has determined to be

10

the customer life. As a practical expedient, we expense sales commissions as incurred when the amortization period of related deferred commission costs would have been one year or less.

Deferred commissions costs paid and payable are included on the condensed consolidated balance sheets within prepaid and other current assets and totaled $331,000 as of April 30, 2019. For the three-month period ended April 30, 2019, $18,000 in amortization expense associated with sales commissions was included in selling, general and administrative expenses on the condensed consolidated statements of operations. There were no impairment losses for these capitalized costs for the three months ended April 30, 2019 and April 30, 2018.

Equity Awards

We account for share-based payments based on the grant-date fair value of the awards with compensation cost recognized as expense over the requisite vesting period. We incurred total compensation expense related to stock-based awards of $269,000 and $222,000 for the three months ended April 30, 2019 and 2018, respectively.

The fair value of the stock options granted is estimated at the date of grant using a Black-Scholes option pricing model. The option pricing model inputs (such as expected term, expected volatility, and risk-free interest rate) impact the fair value estimate. Further, the forfeiture rate impacts the amount of aggregate compensation. These assumptions are subjective and are generally derived from external (such as risk-free rate of interest) and historical (such as volatility factor, expected term, and forfeiture rates) data. Future grants of equity awards accounted for as stock-based compensation could have a material impact on reported expenses depending upon the number, value, and vesting period of future awards.

We periodically issue restricted stock awards in the form of our common stock. The fair value of these awards is based on the market closing price per share on the date of grant. We expense the compensation cost of these awards as the restriction period lapses, which is typically a one- to four-year service period to the Company.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and for tax credit and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing net deferred tax assets, we consider whether it is more likely than not that some or all of the deferred tax assets will not be realized. We establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. The Company maintains a full valuation allowance against its deferred tax assets.

We provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether certain tax positions are more likely than not to be sustained upon examination by tax authorities. We believe we have appropriately accounted for any uncertain tax positions. The Company has recorded $283,000 and $275,000 in reserves for uncertain tax positions and corresponding interest and penalties as of April 30, 2019 and January 31, 2019, respectively.

The Company and its subsidiary are subject to U.S. federal income tax as well as income taxes in multiple state and local jurisdictions. The Company has concluded all U.S. federal tax matters for years through January 31, 2015. All material state and local income tax matters have been concluded for years through January 31, 2014. The Company is no longer subject to IRS examination for periods prior to the tax year ended January 31, 2016; however, carryforward losses that were generated prior to the tax year ended January 31, 2016 may still be adjusted by the IRS if they are used in a future period. 

11

Net Earnings (Loss) Per Common Share

We present basic and diluted earnings per share (“EPS”) data for our common stock. Basic EPS is calculated by dividing the net earnings (loss) attributable to common stockholders of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted EPS is calculated based on the profit or loss attributable to common stockholders and the weighted average number of shares of common stock outstanding, adjusted for the effects of all potential dilutive common stock issuances related to options, unvested restricted stock and convertible preferred stock. Potential common stock dilution related to outstanding stock options and unvested restricted stock is determined using the treasury stock method, while potential common stock dilution related to Series A Convertible Preferred Stock is determined using the “if converted” method.

Our Series A Convertible Preferred Stock are considered participating securities under ASC 260, Earnings Per Share , which means the security may participate in undistributed earnings with common stock. The holders of the Series A Convertible Preferred Stock would be entitled to share in dividends, on an as-converted basis, if the holders of common stock were to receive dividends, other than dividends in the form of common stock. In accordance with ASC 260, the Company is required to use the two-class method when computing EPS. The two-class method is an earnings allocation formula that determines EPS for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. In determining the amount of net earnings to allocate to common stockholders, earnings are allocated to both common and participating securities based on their respective weighted-average shares outstanding for the period. Diluted EPS for our common stock is computed using the more dilutive of the two-class method or the if-converted method. Our unvested restricted stock awards are considered non-participating securities because holders are not entitled to non-forfeitable rights to dividends or dividend equivalents during the vesting term.

In accordance with ASC 260, securities are deemed not to be participating in losses if there is no obligation to fund such losses. The Series A Convertible Preferred Stock does not participate in losses, and as a result, the Company does not allocate losses to these securities in periods of loss.

The following is the calculation of the basic and diluted net earnings (loss) per share of common stock:

 

 

 

 

 

 

 

 

 

Three Months Ended

Basic earnings (loss) per share:

    

April 30, 2019

    

April 30, 2018

Net income (loss)

 

$

313,000

 

$

(569,000)

Less: Allocation of earnings to participating securities

 

 

(40,000)

 

 

 —

Income (loss) available to common shareholders - Basic

 

 

273,000

 

 

(569,000)

Weighted average shares outstanding - Basic (1)

 

 

19,793,361

 

 

19,299,309

Basic net earnings (loss) per share of common stock

 

$

0.01

 

$

(0.03)

 

 

 

 

 

 

 

Diluted earnings (loss) per share (2):

 

 

 

 

 

 

Income (loss) available to common shareholders - Basic

 

 

313,000

 

 

(569,000)

Weighted average shares outstanding - Basic

 

 

19,793,361

 

 

19,299,309

Effect of dilutive securities - Stock options, Restricted stock and Series A Convertible Preferred Stock (3)

 

 

3,031,676

 

 

 —

Weighted average shares outstanding - Diluted

 

 

22,825,037

 

 

19,299,309

Diluted net earnings (loss) per share of common stock

 

$

0.01

 

$

(0.03)


(1)

Excludes 1,104,766 unvested restricted shares of common stock as of April 30, 2019, which are considered non-participating securities.

(2)

Diluted EPS for our common stock was computed using the if-converted method, which yields the same result as the two-class method.

12

(3)

Diluted net earnings (loss) per share excludes the effect of shares that are anti-dilutive. For the three months ended April 30, 2019, diluted EPS excludes 1,583,824 outstanding stock options and 543,750 unvested restricted shares of common stock. For the three months ended April 30, 2018, diluted EPS excludes 2,895,464 shares of Series A Convertible Preferred Stock, 2,178,822 outstanding stock options and 661,587 unvested restricted shares of common stock.

Recent Accounting Pronouncements

In February 2016, the FASB issued ASU 2016‑02, Leases (“ASC 842”), to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The ASU is effective for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. The update became effective for us on February 1, 2019.

We adopted the new lease standards ASC 842 on February 1, 2019 using the effective date transition method. This method requires us to recognize an adoption impact as a cumulative-effect adjustment as of the adoption date. Prior period balances were not adjusted upon adoption this standard. We have elected the group of practical expedients under ASU 2016-02 to forego assessing upon adoption: (1) whether any expired contracts are or contain leases; (2) the lease classification for any existing or expired leases; and (3) any indirect costs that would have qualified for capitalization for any existing leases. The adoption of the new standard resulted in the recording of a right-of-use asset of $175,000 and an operating lease liability of $464,000 as of February 1, 2019. The standard did not materially impact our consolidated results of operations and had no impact on cash flows.

In January 2017, the FASB issued ASU 2017‑04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment , which removes Step 2 from the goodwill impairment test. The standard will be effective for us on February 1, 2020. Early adoption of this update is permitted. We do not expect that the adoption of this ASU will have a significant impact on our consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement , to remove, modify, and add certain disclosure requirements within Topic 820 in order to improve the effectiveness of fair value disclosures in the notes to financial statements. The standard will be effective for us on February 1, 2020. The Company is currently evaluating the impact of adoption of this new standard and does not believe that the adoption of this ASU will have a significant impact on its consolidated financial statements.

 

NOTE 3 — LEASES

We determine whether an arrangement is a lease at inception. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term. Since our lease arrangements do not provide an implicit rate, we use our incremental borrowing rate for the expected remaining lease term at commencement date for new leases, or as of February 1, 2019 for existing leases, in determining the present value of future lease payments. Operating lease expense is recognized on a straight-line basis over the lease term.

Our only operating lease relates to our New York office sublease, which expires in November 2019. In the second quarter of fiscal 2018, we closed our New York office and subleased the office space for the remaining period of the original lease term. As a result of vacating and subleasing the office, we recorded a $472,000 loss on exit of the operating lease in fiscal 2018. The associated lease liability reduced the right-of-use asset upon adoption of ASC 842. As of April 30, 2019, the total minimum rentals due to our lessor by us and to be received by us from our sublessee were $336,000 and $168,000, respectively.

As of April 30, 2019, operating lease right-of use assets totaling $122,000 are recorded in Prepaid and other current assets, and the associated lease liability of $329,000 is included in Accrued expenses within the condensed consolidated balance sheets. The Company used a discount rate of 8.0% to the determine the lease liability.

13

 

Total costs associated with leased assets are as follows:

 

 

 

 

 

    

Three Months Ended April 30, 2019

Operating lease cost

 

$

60,000

Sublease income

 

 

(72,000)

Total operating lease income

 

$

(12,000)

 

In the third quarter of fiscal 2018, we assigned our then current Atlanta office lease that would have expired in November 2022 and entered into a membership agreement to occupy shared office space in Atlanta. As a result of assigning the office lease, we recorded a $562,000 loss on exit of the operating lease in the third quarter of fiscal 2018. The membership agreement does not qualify as a lease under ASC 842 as the owner has substantive substitution rights, therefore the Company recognizes expenses as incurred. See Note 7 – Commitments and Contingencies for further details on our shared office arrangement.

 

NOTE 4 — DEBT

Term Loan and Line of Credit

On November 21, 2014, we entered into a Credit Agreement (the “Credit Agreement”) with Wells Fargo Bank, N.A., as administrative agent, and other lender parties thereto. Pursuant to the Credit Agreement, the lenders agreed to provide a $10,000,000 senior term loan and a $5,000,000 revolving line of credit to our primary operating subsidiary. Amounts outstanding under the Credit Agreement bear interest at either LIBOR or the base rate, as elected by the Company, plus an applicable margin. Subject to the Company’s leverage ratio, pursuant to the terms of the amendment to the Credit Agreement entered into as of April 15, 2015, the applicable LIBOR rate margin varies from 4.25% to 6.25%, and the applicable base rate margin varies from 3.25% to 5.25%. The term loan and line of credit provide support for working capital, capital expenditures and other general corporate purposes, including permitted acquisitions. The outstanding senior term loan is secured by substantially all of our assets. Pursuant to the terms of the fourth amendment to the Credit Agreement entered into as of November 20, 2018, the original term loan and line of credit maturity date of November 21, 2019 was extended to May 21, 2020. The senior term loan principal balance is payable in quarterly installments, which started in March 2015 and will continue through the maturity date, with the full remaining unpaid principal balance due at maturity. Financing costs associated with the credit facility are being amortized over its term on a straight-line basis, which is not materially different from the effective interest method.

The Credit Agreement includes customary financial covenants, including the requirements that the Company maintain minimum liquidity and achieve certain minimum EBITDA levels (as defined in the Credit Agreement). In addition, the Credit Agreement prohibits the Company from paying dividends on the common and preferred stock. Pursuant to the terms of the Credit Agreement, the Company is required to maintain minimum liquidity of at least (i) $5,000,000 through January 31, 2018, (ii) $4,000,000 from February 1, 2018 through November 19, 2018, (iii) $3,500,000 from November 20, 2018 through and including January 31, 2019, and (iv) $4,000,000 from February 1, 2019 through and including the maturity date of the credit facility.

14

The following table shows our minimum EBITDA covenant thresholds, as modified by the fourth amendment to the Credit Agreement:

 

 

 

 

Applicable period

    

Minimum
EBITDA

For the fiscal quarter ended October 31, 2018

 

$

(509,000)

For the 2-quarter period ended January 31, 2019

 

 

20,000

For the 3-quarter period ended April 30, 2019

 

 

204,000

For the 4-quarter period ending July 31, 2019

 

 

180,000

For the 4-quarter period ending October 31, 2019

 

 

508,000

For the 4-quarter period ending January 31, 2020

 

 

408,000

For the 4-quarter period ending April 30, 2020 and each fiscal quarter thereafter

 

 

562,000

 

The Company was in compliance with the applicable financial loan covenants at April 30, 2019.

As of April 30, 2019, the Company had no outstanding borrowings under the revolving line of credit, and had accrued $6,000 in unused line fees. Based upon the borrowing base formula set forth in the Credit Agreement, as of April 30, 2019, the Company had access to the full amount of the $5,000,000 revolving line of credit.

 

Outstanding principal balances on debt consisted of the following at:

 

 

 

 

 

 

 

 

    

April 30, 2019

    

January 31, 2019

Senior term loan

 

$

3,881,000

 

$

4,030,000

Deferred financing cost

 

 

(69,000)

 

 

(82,000)

Total

 

 

3,812,000

 

 

3,948,000

Less: Current portion

 

 

(597,000)

 

 

(597,000)

Non-current portion of debt

 

$

3,215,000

 

$

3,351,000

 

Future principal repayments of debt consisted of the following at April 30, 2019 :

 

 

 

 

Fiscal year

    

Senior Term Loan (1)

2020

 

$

448,000

2021

 

 

3,433,000

Total repayments

 

$

3,881,000


(1)

Term loan balance on the condensed consolidated balance sheet is reported net of deferred financing costs of $69,000.

 

 

NOTE 5 — CONVERTIBLE PREFERRED STOCK

Series A Convertible Preferred Stock

At April 30, 2019, we had 2,895,464 shares of Series A Convertible Redeemable Preferred Stock (the “Preferred Stock”) outstanding. Each share of the Preferred Stock is convertible into one share of the Company’s common stock. The Preferred Stock does not pay a dividend; however, the holders are entitled to receive dividends equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock. The Preferred Stock has voting rights on a modified as-if-converted-to-common-stock-basis. The Preferred Stock has a non-participating liquidation right equal to the original issue price plus accrued unpaid dividends, which are senior to the Company’s common stock. The Preferred Stock can be converted to common shares at any time by the holders, or at the option of the Company if the arithmetic average of the daily volume weighted average price of the common stock for the 10 day period prior to the measurement date is greater than $8.00 per share, and the average daily trading volume for the 60 day period immediately prior to the measurement date exceeds 100,000 shares. The conversion price is $3.00 per share, subject to certain adjustments.

15

At any time following August 31, 2016, subject to the terms of the Subordination and Intercreditor Agreement among the preferred stockholders, the Company and Wells Fargo, which prohibits the redemption of the Preferred Stock without the consent of Wells Fargo, each share of Preferred Stock is redeemable at the option of the holder for an amount equal to the initial issuance price of $3.00 (adjusted to reflect stock splits, stock dividends or similar events) plus any accrued and unpaid dividends thereon. The Preferred Stock is classified as temporary equity as the securities are redeemable solely at the option of the holder.

 

NOTE 6 — INCOME TAXES

Income tax expense consists of federal, state and local tax provisions. For the three months ended April 30, 2019 and 2018, we recorded federal tax expense of zero. For the three months ended April 30, 2019 and 2018, we recorded state and local tax expense of $2,000.

 

NOTE 7 — COMMITMENTS AND CONTINGENCIES

 

Membership agreement to occupy shared office space

In fiscal 2018, the Company entered into a membership agreement to occupy shared office space in Atlanta, Georgia. Our new shared office arrangement commenced upon taking possession of the space and ends in November 2020. Fees due under the membership agreement are based on the number of contracted seats and the use of optional office services. As of April 30, 2019, minimum fees due under the shared office arrangement totaled $232,000.

Royalty Liability

On October 25, 2013, we entered into a Software License and Royalty Agreement (the “Royalty Agreement”) with Montefiore Medical Center (“Montefiore”) pursuant to which Montefiore granted us an exclusive, worldwide 15‑year license of Montefiore’s proprietary clinical analytics platform solution, Clinical Looking Glass® (“CLG”), now known as our Clinical Analytics solution. In addition, Montefiore assigned to us the existing license agreement with a customer using CLG. As consideration under the Royalty Agreement, we paid Montefiore a one-time initial base royalty fee of $3,000,000. Additionally, we originally committed that Montefiore would receive at least an additional $3,000,000 of on-going royalty payments related to future sublicensing of CLG by us within the first six and one-half years of the license term. On July 1, 2018, we entered into a joint amendment to the Royalty Agreement and the existing Software License and Support Agreement with Montefiore to modify the payment obligations of the parties under both agreements. According to the modified provisions, our obligation to pay on-going royalties under the Royalty Agreement was replaced with the obligation to (i) provide maintenance services for 24 months and waive associated maintenance fees, and (ii) pay $1,000,000 in cash by July 31, 2020. As a result of the commitment to fulfill a portion of our obligation by providing maintenance services at no cost, the royalty liability was significantly reduced, with a corresponding increase to deferred revenues. As of January 31, 2019, we had $1,172,000 in deferred revenues associated with this modified royalty liability. The fair value of the royalty liability as of January 31, 2019 was determined based on the amount payable in cash. As of April 30, 2019 and January 31, 2019, the present value of this royalty liability was $920,000 and $905,000, respectively.

NOTE 8 — SUBSEQUENT EVENTS

We have evaluated subsequent events occurring after April 30, 2019, and based on our evaluation we did not identify any events that would have required recognition or disclosure in these condensed consolidated financial statements.  

 

16

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FORWARD-LOOKING STATEMENTS

We make forward-looking statements in this Report and in other materials we file with the Securities and Exchange Commission (“SEC”) or otherwise make public. In this Report, Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements. In addition, our senior management makes forward-looking statements to analysts, investors, the media and others. Statements with respect to expected revenue, income, receivables, backlog, client attrition, acquisitions and other growth opportunities, sources of funding operations and acquisitions, the integration of our solutions, the performance of our channel partner relationships, the sufficiency of available liquidity, research and development, and other statements of our plans, beliefs or expectations are forward-looking statements. These and other statements using words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “target,” “can,” “could,” “may,” “should,” “will,” “would” and similar expressions also are forward-looking statements. Each forward-looking statement speaks only as of the date of the particular statement. The forward-looking statements we make are not guarantees of future performance, and we have based these statements on our assumptions and analyses in light of our experience and perception of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances. Forward-looking statements by their nature involve substantial risks and uncertainties that could significantly affect expected results, and actual future results could differ materially from those described in such statements. Management cautions against putting undue reliance on forward-looking statements or projecting any future results based on such statements or present or historical earnings levels.

Among the factors that could cause actual future results to differ materially from our expectations are the risks and uncertainties described under “Risk Factors” set forth in Part II, Item 1A, and the other cautionary statements in other documents we file with the SEC, including the following:

·

competitive products and pricing;

·

product demand and market acceptance;

·

entry into new markets;

·

new product and services development and commercialization;

·

key strategic alliances with vendors and channel partners that resell our products;

·

uncertainty in continued relationships with clients due to termination rights;

·

our ability to control costs;

·

availability, quality and security of products produced and services provided by third-party vendors;

·

the healthcare regulatory environment;

·

potential changes in legislation, regulation and government funding affecting the healthcare industry;

·

healthcare information systems budgets;

·

availability of healthcare information systems trained personnel for implementation of new systems, as well as maintenance of legacy systems;

·

the success of our relationships with channel partners;

17

·

fluctuations in operating results;

·

our future cash needs;

·

the consummation of resources in researching acquisitions, business opportunities or financings and capital market transactions;

·

the failure to adequately integrate past and future acquisitions into our business;

·

critical accounting policies and judgments;

·

changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or other standard-setting organizations;

·

changes in economic, business and market conditions impacting the healthcare industry and the markets in which we operate;

·

our ability to maintain compliance with the terms of our credit facilities; and

·

our ability to maintain compliance with the continued listing standards of the Nasdaq Global Market.

Most of these factors are beyond our ability to predict or control. Any of these factors, or a combination of these factors, could materially affect our future financial condition or results of operations and the ultimate accuracy of our forward-looking statements. There also are other factors that we may not describe (generally because we currently do not perceive them to be material) that could cause actual results to differ materially from our expectations.

We expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Results of Operations

Revenues

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

 

 

 

 

(in thousands):

    

April 30, 2019

    

April 30, 2018

    

Change

 

% Change

 

 

System sales:

 

 

  

 

 

  

 

 

  

 

  

 

 

Proprietary software - perpetual license

 

$

216

 

$

1,053

 

$

(837)

 

(79)

%

 

Term license

 

 

 —

 

 

43

 

 

(43)

 

(100)

%

 

Hardware and third-party software

 

 

15

 

 

36

 

 

(21)

 

(58)

%

 

Professional services

 

 

581

 

 

238

 

 

343

 

144

%

 

Audit services

 

 

395

 

 

360

 

 

35

 

10

%

 

Maintenance and support

 

 

2,951

 

 

3,309

 

 

(358)

 

(11)

%

 

Software as a service

 

 

1,199

 

 

1,224

 

 

(25)

 

(2)

%

 

Total Revenues

 

$

5,357

 

$

6,263

 

$

(906)

 

(14)

%

 

 

Proprietary software and term licenses  — Proprietary software revenue recognized for the three months ended April 30, 2019 decreased by $837,000 over the prior comparable period. This decrease is attributable to a large perpetual license sale of our Streamline Health® Abstracting™ solution in the first quarter of fiscal 2018.  The Company is able to influence sales of these products; however, the timing is difficult to manage as sales result from our distribution partners or our direct channel from existing customers adding licenses from acquisitions or strategic partnerships. 

18

Hardware and third-party software  — Revenue from hardware and third-party software sales for the three months ended April 30, 2019 decreased by $21,000 from the prior comparable period. Fluctuations from period to period are a function of client demand.

Professional services  — For the three-month period ended April 30, 2019, revenues from professional services increased by $343,000 from the prior comparable period. This increase in professional services revenue is primarily due to the timing of completion of a few, large, professional services agreements.   The Company had previously re-assigned certain professional staff to support the success of eValuator.  However, the Company was able to return these staff to billable projects in the first quarter of fiscal 2019, resulting in higher professional services revenue for the three-month period ended April 30, 2019 over the prior comparable period. The Company is not expecting professional services to recur at these higher revenue levels throughout 2019.

Audit services  — Audit services revenue for the three months ended April 30, 2019 increased by $35,000 over the prior comparable period.  The Company realized higher demand for audit services in the fourth quarter of 2018, and that higher demand has continued into the first quarter of 2019.   The Company’s expertise, demonstrated and supported by eValuator, and the fact that our professional staff is onshore is believed to be a competitive advantage with regard to the audit services provided by the Company. The Company continues to expect higher volumes and revenue of audit services throughout 2019. 

Maintenance and support  — Revenue from maintenance and support for the three months ended April 30, 2019 decreased by $358,000 over the prior comparable period. The decrease is primarily due to pricing pressure and cancellations by certain customers of our legacy products, primarily content management ( ECM). The customer pricing differences and rate of customer cancellations has not exceeded the Company’s budget for fiscal 2019.   The Company has worked the last 12 months to negotiate multi-year agreements on the majority of its current maintenance and support contracts comprising its current, legacy revenue base. This has had the impact of lowering revenues in a given quarter (exchanging lower revenue per quarter for longer, sustained revenue).   The lower quarterly revenues, as compared to quarterly revenues in the prior year, will continue throughout fiscal 2019.

Software as a Service (SaaS)  — Revenue from SaaS for the three months ended April 30, 2019 decreased by $25,000 from the prior comparable period. This decrease resulted primarily from cancellations by a few customers of our legacy products, primarily our financial management software. The growth in eValuator revenue overcame a portion of the revenue loss from financial management. The Company is expecting net revenue growth as eValuator is expected to overcome any loss of revenue from financial management software in fiscal 2019.

Cost of Sales

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

 

 

 

(in thousands):

    

April 30, 2019

    

April 30, 2018

    

Change

 

% Change

 

Cost of system sales

 

$

113

 

$

250

 

$

(137)

 

(55)

%

Cost of professional services

 

 

542

 

 

706

 

 

(164)

 

(23)

%

Cost of audit services

 

 

303

 

 

394

 

 

(91)

 

(23)

%

Cost of maintenance and support

 

 

409

 

 

648

 

 

(239)

 

(37)

%

Cost of software as a service

 

 

280

 

 

316

 

 

(36)

 

(11)

%

Total cost of sales

 

$

1,647

 

$

2,314

 

$

(667)

 

(29)

%

 

The decrease in overall cost of sales for the three months ended April 30, 2019 from the comparable prior period is primarily due to the reduction in depreciation and amortization as well as a reduction in client support personnel costs.  As previously disclosed, the Company has lower depreciation and amortization due to certain assets being fully amortized and impairments of certain assets from previous quarters.

Cost of system sales includes amortization and impairment of capitalized software expenditures and the cost of third-party hardware and software. The decrease in expense for the three-month period ended April 30, 2019 from the comparable prior period was primarily due to the reduction in amortization of capitalized software costs as a result of assets becoming fully amortized, including our internally-developed software.

19

The cost of professional services includes compensation and benefits for personnel and related expenses. The decrease in expense for the three-month period from the prior comparable period is primarily due to the decrease in professional services related to SaaS implementations, for which costs are deferred and amortized ratably over the estimated life of the SaaS customer relationship.  The Company is getting more productivity from professional staff on the implementation of SaaS related engagements as compared to the legacy on-premise software implementations. On-premise implementations, as was the case with legacy software products implementations, took longer and involved more cost. 

The cost of audit services includes compensation and benefits for audit services personnel, and related expenses. The decrease in expense for the three-month period ended April 30, 2019 is attributed to the reduction in personnel.  The Company audit services personnel utilize eValuator and it is believed that the product makes them more productive and efficient. 

The cost of maintenance and support includes compensation and benefits for client support personnel and the cost of third-party maintenance contracts. The decrease in expense for the three-month period ended April 30, 2019 was primarily due to a decrease in personnel costs and a reduction in third-party maintenance contracts.

The cost of SaaS solutions is relatively fixed, subject to inflation for the goods and services it requires. The decrease in expense for the three-month period ended April 30, 2019 was primarily due to the reduction in depreciation expense as a result of data center equipment becoming fully depreciated.

Selling, General and Administrative Expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

 

 

 

(in thousands):

    

April 30, 2019

    

April 30, 2018

    

Change

 

% Change

 

General and administrative expenses

 

$

1,708

 

$

2,188

 

$

(480)

 

(22)

%

Sales and marketing expenses

 

 

776

 

 

1,062

 

 

(286)

 

(27)

%

Total selling, general, and administrative expense

 

$

2,484

 

$

3,250

 

$

(766)

 

(24)

%

 

General and administrative expenses consist primarily of compensation and related benefits, reimbursable travel and entertainment expenses related to our executive and administrative staff, general corporate expenses, amortization of intangible assets, and occupancy costs. The decrease in general and administrative expenses for the three months ended April 30, 2019 from the comparable prior period is primarily attributed to a reduction in facility cost, bad debt expense and in amortization of intangible assets.  We previously disclosed the Company’s reduction in facility cost due to relocation of the corporate headquarters in Atlanta, Georgia and subleasing of the New York City office. The decrease in facility cost saved the Company approximately $280,000 (for the lease cost alone), in the first quarter of fiscal 2019 compared with the same period in fiscal 2018.  The Company recorded a benefit of approximately $280,000 that reduced its allowance of doubtful accounts due to collection successes and a reduction in the total amount and aging of its accounts receivable.  These favorable cost savings were offset by an increase in professional fees in the first quarter of fiscal 2019 over the prior comparable period.   The Company records a disproportionate amount of professional fees in the first quarter of fiscal 2019 attributable to the annual audit and the Company’s annual shareholder meeting.  This disproportionate amount of professional fees occurred in both three-month periods ended April 30, 2019 and 2018.   

Sales and marketing expenses consist primarily of compensation and related benefits and reimbursable travel and entertainment expenses related to our sales and marketing staff, as well as advertising and marketing expenses, including trade shows. The decrease in sales and marketing expense for the three months ended April 30, 2019 from the comparable prior period was primarily due to a reduction in personnel cost, trade shows expense, and sales, marketing, and investor relations consultant fees.  The Company has re-focused its sales and marketing dollars.  The targeted and focused approach has resulted in fewer dollars that have a higher return.

 

20

Research and Development

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

 

 

 

 

(in thousands):

    

April 30, 2019

    

April 30, 2018

    

Change

 

% Change

 

 

Research and development expense

 

$

792

 

$

1,062

 

$

(270)

 

(25)

%

 

Plus: Capitalized research and development cost

 

 

970

 

 

726

 

 

244

 

34

%

 

Total research and development cost

 

$

1,762

 

$

1,788

 

$

(26)

 

(1)

%

 

 

Research and development cost consists primarily of compensation and related benefits, the use of independent contractors for specific near-term development projects, and allocated occupancy expense. Total research and development cost for the three-month period ended April 30, 2019 was consistent with that from the prior comparable period.  The Company spent, however, more dollars on capitalized research and development cost due to the effort on eValuator development.  The Company is spending fewer dollars on maintenance for its legacy products from its engineering group as these products have attained maturity in the marketplace.  The Company is expecting that total research and development expenses will continue at these levels for another quarter, and then decrease toward the end of fiscal 2019.  For the three months ended April 30, 2019 and 2018, as a percentage of revenues, total research and development costs were 33% and 29%, respectively.  The higher percentage of total research and development cost over revenues is consistent with our Company investing in its most recent product, eValuator.

Other Expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

 

 

 

(in thousands):

    

April 30, 2019

    

April 30, 2018

    

Change

 

% Change

 

Interest expense

 

$

(78)

 

$

(116)

 

$

38

 

(33)

%

Miscellaneous expense

 

 

(41)

 

 

(88)

 

 

47

 

(53)

%

Total other expense

 

$

(119)

 

$

(204)

 

$

85

 

(42)

%

 

Interest expense consists of interest and commitment fees on the line of credit, interest on the term loan, and is inclusive of deferred financing cost amortization expense. Interest expense decreased for the three months ended April 30, 2019 from the prior comparable period primarily due to the reduction in outstanding principal on our term loan and the increase in capitalized interest on our internally developed software. The fluctuation in miscellaneous expense for the three-month period ended April 30, 2019 from the prior comparable period is primarily due to the decrease in revaluation adjustments to our royalty liability, which was significantly reduced in the second quarter of fiscal 2018 as a result of the commitment to fulfill a portion of our obligation by providing maintenance services at no cost.

Provision for Income Taxes

We recorded tax expense of $2,000 for the three months ended April 30, 2019 and 2018, which is comprised of estimated federal, state and local tax provisions.

Use of Non-GAAP Financial Measures

In order to provide investors with greater insight, and allow for a more comprehensive understanding of the information used by management and the Board of Directors in its financial and operational decision-making, the Company has supplemented the Condensed Consolidated Financial Statements presented on a GAAP basis in this quarterly report on Form 10‑Q with the following non-GAAP financial measures: EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin and Adjusted EBITDA per diluted share.

These non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for analysis of Company results as reported under GAAP. The Company compensates for such limitations by relying primarily on our GAAP results and using non-GAAP financial measures only as supplemental data. We also provide a reconciliation of non-GAAP to GAAP measures used. Investors are encouraged to carefully review this reconciliation. In addition, because these non-GAAP measures are not measures of financial performance under GAAP

21

and are susceptible to varying calculations, these measures, as defined by us, may differ from and may not be comparable to similarly titled measures used by other companies.

EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, and Adjusted EBITDA per diluted share

We define: (i) EBITDA as net earnings (loss) before net interest expense, income tax expense (benefit), depreciation and amortization; (ii) Adjusted EBITDA as net earnings (loss) before net interest expense, income tax expense (benefit), depreciation, amortization, stock-based compensation expense, transaction expenses and other expenses that do not relate to our core operations; (iii) Adjusted EBITDA Margin as Adjusted EBITDA as a percentage of GAAP net revenue; and (iv) Adjusted EBITDA per diluted share as Adjusted EBITDA divided by adjusted diluted shares outstanding. EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin and Adjusted EBITDA per diluted share are used to facilitate a comparison of our operating performance on a consistent basis from period to period and provide for a more complete understanding of factors and trends affecting our business than GAAP measures alone. These measures assist management and the board and may be useful to investors in comparing our operating performance consistently over time as they remove the impact of our capital structure (primarily interest charges), asset base (primarily depreciation and amortization), items outside the control of the management team (taxes), and expenses that do not relate to our core operations including: transaction-related expenses (such as professional and advisory services), corporate restructuring expenses (such as severances), and other operating costs that are expected to be non-recurring. Adjusted EBITDA removes the impact of share-based compensation expense, which is another non-cash item. Adjusted EBITDA per diluted share includes incremental shares in the share count that are considered anti-dilutive in a GAAP net loss position.

The Board of Directors and management also use these measures as (i) one of the primary methods for planning and forecasting overall expectations and for evaluating, on at least a quarterly and annual basis, actual results against such expectations; and (ii) as a performance evaluation metric in determining achievement of certain executive and associate incentive compensation programs.

Our lender uses a measurement that is similar to the Adjusted EBITDA measurement described herein to assess our operating performance. The lender under our Credit Agreement requires delivery of compliance reports certifying compliance with financial covenants, certain of which are based on a measurement that is similar to the Adjusted EBITDA measurement reviewed by our management and Board of Directors.

EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin are not measures of liquidity under GAAP, or otherwise, and are not alternatives to cash flow from continuing operating activities, despite the advantages regarding the use and analysis of these measures as mentioned above. EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, and Adjusted EBITDA per diluted share, as disclosed in this quarterly report on Form 10‑Q, have limitations as analytical tools, and you should not consider these measures in isolation or as a substitute for analysis of our results as reported under GAAP; nor are these measures intended to be measures of liquidity or free cash flow for our discretionary use. Some of the limitations of EBITDA, and its variations are:

·

EBITDA does not reflect our cash expenditures or future requirements for capital expenditures or contractual commitments;

·

EBITDA does not reflect changes in, or cash requirements for, our working capital needs;

·

EBITDA does not reflect the interest expense, or the cash requirements to service interest or principal payments under our credit agreement;

·

EBITDA does not reflect income tax payments that we may be required to make; and

·

Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized often will have to be replaced in the future, and EBITDA does not reflect any cash requirements for such replacements.

22

Adjusted EBITDA has all the inherent limitations of EBITDA. To properly and prudently evaluate our business, we encourage readers to review the GAAP financial statements included elsewhere in this quarterly report on Form 10‑Q, and not rely on any single financial measure to evaluate our business. We also strongly urge readers to review the reconciliation of these non-GAAP financial measures to the most comparable GAAP measure in this section, along with the Condensed Consolidated Financial Statements included elsewhere in this quarterly report on Form 10‑Q.

The following table sets forth a reconciliation of EBITDA and Adjusted EBITDA to net income (loss), the most comparable GAAP-based measure, as well as Adjusted EBITDA per diluted share to net earnings (loss) per diluted share. All of the items included in the reconciliation from EBITDA and Adjusted EBITDA to income (loss) and the related per share calculations are either recurring non-cash items, or items that management does not consider in assessing our on-going operating performance. In the case of the non-cash items, management believes that investors may find it useful to assess our comparative operating performance because the measures without such items are less susceptible to variances in actual performance resulting from depreciation, amortization and other expenses that do not relate to our core operations and are more reflective of other factors that affect operating performance. In the case of items that do not relate to our core operations, management believes that investors may find it useful to assess our operating performance if the measures are presented without these items because their financial impact does not reflect ongoing operating performance.

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

In thousands, except per share data

   

April 30, 2019

  

April 30, 2018

 

Adjusted EBITDA Reconciliation

 

 

 

 

 

 

 

Net income (loss)

 

$

313

 

$

(569)

 

Interest expense

 

 

78

 

 

116

 

Income tax expense

 

 

 2

 

 

 2

 

Depreciation

 

 

35

 

 

171

 

Amortization of capitalized software development costs

 

 

206

 

 

315

 

Amortization of intangible assets

 

 

143

 

 

235

 

Amortization of other costs

 

 

50

 

 

103

 

EBITDA

 

 

827

 

 

373

 

Share-based compensation expense

 

 

269

 

 

222

 

Gain on disposal of fixed assets

 

 

 —

 

 

(2)

 

Non-cash valuation adjustments to assets and liabilities

 

 

15

 

 

51

 

Adjusted EBITDA

 

$

1,111